Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22175017 | 0.83 | KDM4E (0.42) | KDM4EALDH1A1ALOX15KMT2AMEN1 | |
| SCHEMBL25001758 | 0.81 | L3MBTL1 (0.39) | KDM4EALDH1A1KMT2AMEN1MC4R | |
| SCHEMBL1286703 | 0.80 | TSHR (0.45) | ALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL4541000 | 0.78 | L3MBTL3 (0.32) | KMT2A | |
| SCHEMBL17308256 | 0.77 | TSHR (0.38) | ALDH1A1KMT2AMEN1TSHR | |
| SCHEMBL14355433 | 0.77 | KDM4E (0.53) | KDM4EALDH1A1ALOX15KMT2AMEN1 | |
| SCHEMBL18976856 | 0.77 | KDM4E (0.53) | KDM4EALDH1A1ALOX15KMT2AMEN1 | |
| SCHEMBL3421713 | 0.74 | PIK3CD (0.45) | KDM4EPOLBTSHR | |
| SCHEMBL736384 | 0.73 | ACHE (0.52) | KDM4EALDH1A1ALOX15KMT2AMEN1 | |
| SCHEMBL736828 | 0.73 | ACHE (0.52) | KDM4EALDH1A1ALOX15KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | KDM4E 1474/4885ALDH1A1 4260/4885ALOX15 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.